Mounjaro®
Starting from £179.99/mo
Start journey Learn moreSemaglutide begins working almost immediately after your first dose, but noticeable weight change typically takes four to eight weeks. In the STEP 1 clinical trial, adults using the 2.4 mg dose lost an average of around 15% of their body weight over 68 weeks alongside lifestyle changes. That headline figure is real, but the pace matters as much as the destination. Semaglutide is a prescription-only medicine, and a prescriber will assess your individual situation before treatment starts.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Semaglutide works by binding to GLP-1 receptors in the gut and brain. It slows gastric emptying (food moves more gradually from the stomach into the small intestine) and sends stronger satiety signals to the brain. Most people notice a quieter appetite within the first week or two. Meals feel filling sooner. The urge to snack often fades. What does not happen immediately is a dramatic shift on the scales.
The first four weeks are usually at the 0.25 mg starting dose, which is a tolerability step, not the therapeutic level. The body is adjusting to the medicine rather than being treated at full effect. Some people do see modest weight loss in this phase; others see very little. Both are normal. If you are wondering how fast semaglutide works for weight loss and what to expect at each stage, it helps to know that slow early progress most often means the titration is doing its job, keeping side effects manageable while the dose builds.
For a closer look at what the first few months tend to look like in practice, our page on how long semaglutide takes to work walks through the timeline in more detail.
Meaningful loss (enough to notice on the scales or in how clothes fit) typically begins between weeks four and twelve, as the dose increases toward the maintenance level. The NHS medicines information for semaglutide describes the graduated dosing pathway: 0.25 mg rising through 0.5 mg, 1.0 mg, 1.7 mg to 2.4 mg, with each step held for roughly four weeks. By the time a person reaches or nears the maintenance dose, appetite suppression is usually at its strongest.
In the STEP 1 trial, published in the New England Journal of Medicine, participants who received 2.4 mg semaglutide lost weight most rapidly in the first 20 weeks, with the rate slowing but continuing through to 68 weeks. The average reduction was around 15%, with many participants losing more and some less. Individual variation is wide, and that is not a flaw in the evidence, it reflects genuine differences in metabolism, starting weight, adherence and lifestyle.
People who want to understand how fast semaglutides work across the class sometimes find our page on semaglutide at ten weeks a useful reference for early-stage expectations.
Yes, and this is worth understanding before you start. Weight loss with semaglutide tends to be steepest in the first six months, then levels off. By the time someone has been on the maintenance dose for several months, the body has adapted its energy balance, and weekly loss becomes smaller. This plateau is physiologically normal, it is not the medicine wearing off.
Several factors genuinely affect how fast semaglutide works for any individual. The dose reached matters: those who tolerate 2.4 mg (or, with the newer 7.2 mg pen, a higher dose) tend to see greater average loss than those who stay at a lower maintenance level. Consistency matters too, missed doses or prolonged breaks reset the curve. And the lifestyle piece is real: the trial evidence assumes a reduced-calorie diet alongside treatment.
It is also worth knowing that the NICE recommendation for semaglutide (Wegovy) includes a review point at six months: if less than 5% weight loss has occurred on the maintenance dose, continuing is reconsidered. That is a clinical safeguard, not a verdict on effort.
For context on how this compares with tirzepatide, our treatment overview covers both options side by side.
In January 2026 the MHRA approved a 7.2 mg dose of semaglutide (Wegovy), and a dedicated single-dose 7.2 mg pen received approval in April 2026. Trial data reported average weight loss of around 20.7% over 72 weeks at this dose, approaching the results seen with tirzepatide 15 mg in the SURMOUNT programme. The titration schedule and clinical requirements are the same, a prescriber still decides whether this dose is appropriate.
The speed of action does not fundamentally change at the higher dose: appetite suppression still builds gradually through titration. What changes is the ceiling. People who have reached 2.4 mg and plateaued earlier than expected may find that moving toward 7.2 mg, under clinical supervision, restarts meaningful progress. Whether that applies to you is exactly the kind of question a prescriber weighs up during a consultation review.
If you are thinking about starting treatment and want to understand how fast Wegovy works in practice from week one, that page covers the clinical detail. When you're ready to talk to a prescriber about whether semaglutide is right for you, starting your free consultation is the first step.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.